QG3030 Phase 1 Trial Progresses; Q Genetics Eyes Global Tech Transfer by 2026
Q Genetics Co., Ltd. (CEO: Chang, Mun Seog) has announced significant progress in the clinical Phase 1 trial of its treatment drug "QG3030" for menopausal obesity and osteoporosis. The company has embarked on its global technology transfer initiative, targeting completion by the first half of 2026. Recently, Q Genetics secured investment from K-Ground Partners' IP Fund, giving impetus to its new drug development endeavors. Subsequent to the completion of its Phase 1 trial, the company has initiated active business development (BD) activities, including research publications and engagement with global stakeholders, centered in Boston, USA, to facilitate global technology licensing. Leveraging its domestic and international patents, Q Genetics has expedited its global technology transfer process with support from K-Ground Partners' IP Fund. The fund specializes in identifying companies with intellectual property (IP) assets capable of generating revenue. Q Genetics has successfully registered patents for its small-molecule compound for osteoporosis treatment in key countries such as South Korea, Japan, China, and India, while patent applications in the United States and Europe are currently under review. Additionally, Q Genetics achieved success in synthesizing and optimizing production processes for its osteoporosis and menopausal obesity drug candidates. The company has published these findings in leading chemistry journals such as Organic Letters and Organic Process Research & Development. The ongoing Phase 1 clinical trial is expected to be completed by Q2 2025, focusing on securing global technology transfer agreements and further investments. In February 2025, Q Genetics participated in the Seoul Bio Hub Global Expansion Growth Acceleration Program. During this program, the company held meetings with global pharmaceutical companies and investors at the Cambridge Innovation Center (CIC) in Boston, receiving positive feedback. In March 2025, Q Genetics successfully completed its single-dose safety trial as part of Phase 1 clinical testing. The company plans to conduct repeated-dose trials before the second half of this year to finalize Phase 1 clinical trials within 2025 and prepare for Phase 2 trials. A representative from Q Genetics stated: "Through the successful development of QG3030, we aim to provide new treatment options for patients suffering from osteoporosis and menopausal obesity while strengthening our competitiveness in the global market." 최지원 기자genetics transfer technology transfer its phase osteoporosis treatment
